Compare IHT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IHT | CANF |
|---|---|---|
| Founded | 1971 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 4.7M |
| IPO Year | 1995 | 2011 |
| Metric | IHT | CANF |
|---|---|---|
| Price | $1.05 | $3.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | 9.7K | ★ 606.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,600,000.00 | N/A |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | $290,391.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.33 | N/A |
| 52 Week Low | $0.95 | $0.17 |
| 52 Week High | $4.24 | $10.40 |
| Indicator | IHT | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 39.85 | 39.07 |
| Support Level | $1.03 | $0.60 |
| Resistance Level | $1.27 | $4.74 |
| Average True Range (ATR) | 0.04 | 0.69 |
| MACD | 0.01 | -0.19 |
| Stochastic Oscillator | 39.55 | 1.07 |
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.